menu
The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030
The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030
Benefits offered by microbial biomanufacturing, such as lowproduction costs and faster development timelines, have led many innovators toadopt these platforms for next generation biologics, offering lucrativeopportunities for CMOs / CDMOs

Benefits offered by microbial biomanufacturing, such as lowproduction costs and faster development timelines, have led many innovators toadopt these platforms for next generation biologics, offering lucrativeopportunities for CMOs / CDMOs

 

Roots Analysis is pleased toannounce the publication of its recent study, titled, “MicrobialContract Biomanufacturing Market, 2020-2030.

 

Thereport features an extensive study of the current market landscape and futureopportunities associated with the microbial contract biomanufacturing market. Itfeatures a detailed analysis of key drivers and trends related to this evolvingdomain. In addition to other elements, the study includes:

§  Adetailed review of the current landscape of companies offering contractmanufacturing services.

§  Elaborateprofiles of key players that specialize in offering services for contract biomanufacturing.

§  A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.

§  Ananalysis of the partnerships and expansions that have been established in thisdomain, in the recent past.

§  A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.

§  Adetailed proprietary 2×2 representation to assess the current market scenario

§  Ananalysis of the initiatives of big biopharma players engaged in this domain.

§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)

§ Type of Product

§ API

§ FDF

 

§  Typeof Biologic

§  Proteins

§  Enzymes

§  GrowthHormones

§  Antibodybased Drugs

§  Others(plasmid DNA, probiotics, microbiome-based biologics)

 

§ Type of Microbial Expression System

§  Bacteria

§  Yeast

§  Others(Algae and fungi)

 

§  Scaleof Operation

§  Commercial

§  Preclinical/ Clinical

 

§  Typeof End User

§  SmallCompanies

§  Mid-sizedCompanies

§  Large/ Very Large Companies

 

§  KeyGeographical Regions

§  NorthAmerica

§  Europe

§  AsiaPacific

§  MiddleEast and North Africa

§  LatinAmerica

 

Transcripts of interviews held with thefollowing senior level representatives of stakeholder companies

§  Gaurav Kaushik (ChiefExecutive Officer and Managing Director, MeteoricBiopharmaceuticals)

§  Debbie Pinkston (VicePresident, Sales and Business Development, List Biological Laboratories)

§  Andrea Conforto(Sales and Marketing, Bioservices Director, Olon)

§  Max Rossetto (GeneralManager, Business Development, LuinaBio)

§  Rob van Dijk(Business Development Manager, WACKERBiotech)

 

 

Keycompanies covered in the report

§  AGCBiologics

§  Aldevron

§  BioVectra

§  EirGenix

§  Etinpro

§  Eurogentec

§  NorthwayBiotechpharma

§  OlogyBioservices

§  PortonBiopharma

§  StelisBiopharma

 

For additionaldetails, please visit 

https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html oremail sales@rootsanalysis.com

 

You may also beinterested in the following titles:

1.    DrugRepurposing Service Providers Market, 2020 – 2030

2.    AntibodyDiscovery Services and Platforms Market (3rd Edition), 2020-2030

3.    LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active PharmaceuticalIngredients and Finished Dosage Forms, 2020 - 2030

 

Contact:

Gaurav Chaudhary

+1(415) 800 3415

+44(122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com